Abstract
Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor and antiangiogenic activities of sunitinib malate, a potent inhibitor of two receptors involved in angiogenesis – vascular endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR). In the present study, we reported that treatment of HepG2 and SK-Hep-1 cells with sunitinib led to growth inhibition and apoptosis in a dose-dependent fashion. Sunitinib inhibited phosphorylation of VEGFR-2 at Tyr951 and PDGFR-β at Tyr1021 both in vitro and in vivo. Sunitinib also suppressed tumor growth of five patient-derived xenografts. Sunitinib-induced tumor growth inhibition was associated with increased apoptosis, reduced microvessel density and inhibition of cell proliferation. This study provides a strong rationale for further clinical investigation of sunitinib in patients with hepatocellular carcinoma.
Keywords: Sunitinib, hepatocellular carcinoma, growth inhibition, anti-angiogenesis
Current Cancer Drug Targets
Title: Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma
Volume: 9 Issue: 6
Author(s): H. Huynh, V. C. Ngo, S. P. Choo, D. Poon, H. N. Koong, C. H. Thng, H. C. Toh, L. Zheng, L. C. Ong, Y. Jin, I. C. Song, A. P.C. Chang, H. S. Ong, A. Y.F. Chung, P. K.H. Chow and K. C. Soo
Affiliation:
Keywords: Sunitinib, hepatocellular carcinoma, growth inhibition, anti-angiogenesis
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common and third deadliest primary neoplasm. Since HCC is a particularly vascular solid tumor, we determined the antitumor and antiangiogenic activities of sunitinib malate, a potent inhibitor of two receptors involved in angiogenesis – vascular endothelial growth factor receptor (VEGFR) and plateletderived growth factor receptor (PDGFR). In the present study, we reported that treatment of HepG2 and SK-Hep-1 cells with sunitinib led to growth inhibition and apoptosis in a dose-dependent fashion. Sunitinib inhibited phosphorylation of VEGFR-2 at Tyr951 and PDGFR-β at Tyr1021 both in vitro and in vivo. Sunitinib also suppressed tumor growth of five patient-derived xenografts. Sunitinib-induced tumor growth inhibition was associated with increased apoptosis, reduced microvessel density and inhibition of cell proliferation. This study provides a strong rationale for further clinical investigation of sunitinib in patients with hepatocellular carcinoma.
Export Options
About this article
Cite this article as:
Huynh H., Ngo C. V., Choo P. S., Poon D., Koong N. H., Thng H. C., Toh C. H., Zheng L., Ong C. L., Jin Y., Song C. I., Chang P.C. A., Ong S. H., Chung Y.F. A., Chow K.H. P. and Soo C. K., Sunitinib (SUTENT, SU11248) Suppresses Tumor Growth and Induces Apoptosis in Xenograft Models of Human Hepatocellular Carcinoma, Current Cancer Drug Targets 2009; 9 (6) . https://dx.doi.org/10.2174/156800909789271530
DOI https://dx.doi.org/10.2174/156800909789271530 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry In Situ Modulation of Oxidative Stress: A Novel and Efficient Strategy to Kill Cancer Cells
Current Medicinal Chemistry Protective Effects of Incretin Against Age-Related Diseases
Current Drug Delivery Inhibition of Glycolysis and Glutaminolysis: An Emerging Drug Discovery Approach to Combat Cancer
Current Topics in Medicinal Chemistry Circulating microRNAs as Potential Diagnostic Biomarkers and Therapeutic Targets in Gastric Cancer: Current Status and Future Perspectives
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Pleiotropic Beneficial Effects of Epigallocatechin Gallate, Quercetin and Delphinidin on Cardiovascular Diseases Associated with Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry Understanding Nutritional Interventions and Physical Exercise in Non-Alcoholic Fatty Liver Disease
Current Molecular Medicine The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Irritable Bowel Syndrome: A Clinical Review
Current Rheumatology Reviews Hypothetical Link Between Infertility and Genetically Modified Food
Recent Patents on Food, Nutrition & Agriculture Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets N-Myristoyltransferase: A Novel Target
Mini-Reviews in Medicinal Chemistry Patent Selections
Recent Patents on DNA & Gene Sequences Molecular Profiles of Sentinel and Non-Sentinel Lymph Nodes in Breast Cancer Progression and Prognosis
Current Cancer Therapy Reviews New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Ghrelin, A Novel Peptide Hormone in the Regulation of Energy Balance and Cardiovascular Function
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery In silico Methods for Designing Antagonists to Anti-apoptotic Members of Bcl-2 Family Proteins
Mini-Reviews in Medicinal Chemistry